Haemonetics (HAE) Misses Q4 EPS by 5c; Guides FY16 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Haemonetics (HAE) Misses Q4 EPS by 5c; Guides FY16 EPS
April 28, 2015 11:11 AM EDT
Haemonetics's (NYSE: HAE) Strong Sell recommendation was removed at Off Wall Street after the company reported Q4 results and guidance, according to sources. Analysts noted FY16 guidance implies revenue and EPS growth.
...
More
April 28, 2015 9:38 AM EDT
Barrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform with a price target of $44.00. The change follows Q4 results and guidance.
Analyst Michael Petusky, "While we like many aspects of the Haemonetics story, particularly longer term, we do not see the... More
April 28, 2015 8:38 AM EDT
Jefferies analyst Anthony Petrone reiterated a Buy rating and bumped his price target on Haemonetics (NYSE: HAE) to $48.00 (from $45.00) following Q4 results. The analyst said while FX was unavoidable the underlying trends support a rebound in FY16.
Petrone commented, "HAE... More
